Research
Hormonal
Administration of the bacterium Akkermansia muciniphila reverses hyperglycemia and reduces body weight in murine models of obesity and type 2 diabetes.
While A. muciniphila shows promise in mice for reversing diabetes and obesity, human results are mixed. Focus on prebiotics like oligofructose, which naturally increase A. muciniphila levels and have shown metabolic benefits in humans, rather than seeking unproven bacterial supplements.
ModerateSupportsMEDIUM confidence
When treating these animals via administration of A muciniphila, body weight was reduced and hyperglycaemia reversed.
Why this rating
Strong evidence in murine models (Everard et al.), but human data is conflicting (Qin et al. vs. Zhang et al.).
Source
Microbiota and diabetes: an evolving relationship
Herbert Tilg et al. · Gut · 2014
DOI 10.1136/gutjnl-2014-306928
narrative_reviewCited 830×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →